Kolaviron, a Garcinia biflavonoid complex ameliorates hyperglycemia-mediated hepatic injury in rats via suppression of inflammatory responses

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Ayepola, Omolola R ^a   Chegou, Novel N ^b   Brooks, Nicole L ^a   Oguntibeju, Oluwafemi O ^a  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Chemotactic protein; Diabetes; Hepatic injury; Kolaviron; Pro inflammatory cytokine

Indexed keywords

CHEMOKINE; GLUCOSE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; KOLAVIRON; MONOCYTE CHEMOTACTIC PROTEIN 1; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYZER; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC KIT; DRUG EFFECT; DRUG ISOLATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; LIVER DYSFUNCTION; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RAT; TREATMENT DURATION; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DRUG-INDUCED LIVER INJURY; FLAVONOIDS; GARCINIA KOLA; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; LIVER; MALE; ORGAN SIZE; PLANT EXTRACTS; RATS; RATS, WISTAR; SEEDS; STREPTOZOCIN;

EID: 84890514150     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-363     Document Type: Article

References (61)

1. Yoon J, Jun H. Autoimmune destruction of pancreatic beta cells. Am J Therapeut 2005, 12(6):580-591.
2. Zanatta L, de Sousa E, Cazarolli LH, Junior AC, Pizzolatti MG, Szpoganicz B, Silva FR, Barreto M. Effect of crude extract and fractions from Vitex megapotamica leaves on hyperglycemia in alloxan-diabetic rats. J Ethnopharmacol 2007, 109(1):151-155. 10.1016/j.jep.2006.07.019, 16930892.
3. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 2003, 108(13):1655-1661. 10.1161/01.CIR.0000089189.70578.E2, 14517152.
4. Fisher EB, Thorpe CT, DeVellis BM, DeVellis RF. Healthy coping, negative emotions, and diabetes management, a systematic review and appraisal. Diabetes Educ 2007, 33(6):1080-1103. 10.1177/0145721707309808, 18057276.
5. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008, 26(2):77-82.
6. Kim JY, Lee SH, Song EH, Park YM, Lim J, Kim DJ, Choi K, Park SI, Gao B, Kim W. A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: controlled by ATF3. Cell Signal 2009, 21(12):1758-1767. 10.1016/j.cellsig.2009.07.011, 19647793.
7. Ingaramo PI, Francés DE, Ronco MT, Carnovale CE. Diabetes and Its hepatic complication. Hot topics in endocrine and endocrine-related diseases 2013, InTech, Fedele M, ISBN: 978-953-51-1080-4, doi:10.5772/53684.
8. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006, 40(1):68-76. 10.1097/01.mcg.0000190774.91875.d2, 16340637.
9. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Investig 2005, 115(5):1111-1119. 1087185, 15864338.
10. Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, Diamanti-Kandarakis E, Kaltsas G, Kalofoutis A. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol 2008, 28(4):314-321. 10.1007/s10875-007-9164-1, 18224429.
11. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19(3):433-442. 10.1681/ASN.2007091048, 18256353.
12. Martin-Sanz P, Hortelano S, Callejas NA, Goren N, Casado M, Zeini M, Boscá L. Nitric oxide in liver inflammation and regeneration. Metab Brain Dis 2002, 17(4):325-334. 10.1023/A:1021909902310, 12602509.
13. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17(1):4-12.
14. Hussain RA, Owegby AG, Parimoo P, Eatomam PG. Kolavonone, a novel polyisoprenylated benzophenone with antimicrobial properties from fruit of Garcinia kola. J Med Plan Res 1982, 44:78-81.
15. Iwu M, Igboko O. Flavonoids of Garcinia kola seeds. J Nat Prod 1982, 45(5):650-651.
16. Iwu M. Antihepatoxic constituents of Garcinia kola seeds. Experientia 1985, 41(5):699-700. 10.1007/BF02007729, 3838940.
17. Abarikwu SO, Farombi EO, Pant AB. Kolaviron biflavanoids of Garcinia Kola seeds protect atrazine-induced cytotoxicity in primary cultures of rat leydig cells. Int J Toxicol 2012, 31(4):407-415. 10.1177/1091581812445476, 22674924.
18. Adedara I, Vaithinathan S, Jubendradass R, Mathur P, Farombi E. Kolaviron prevents carbendazim-induced steroidogenic dysfunction and apoptosis in testes of rats. Environ Toxicol Pharmacol 2013, 35:444-453. 10.1016/j.etap.2013.01.010, 23474402.
19. Farombi EO, Adedara IA, Ajayi BO, Ayepola OR, Egbeme EE. Kolaviron, a natural antioxidant and anti-inflammatory phytochemical prevents dextran sulphate sodium-induced colitis in rats. Basic Clin Pharmacol Toxicol 2013, 113(1):49-55. 10.1111/bcpt.12050, 23336970.
20. Adedara IA, Farombi EO. Chemoprotection of ethylene glycol monoethyl ether- induced reproductive toxicity in male rats by kolaviron, isolated biflavonoid from Garcinia kola seed. Hum Exp Toxicol 2012, 31:506-517. 10.1177/0960327111424301, 22027498.
21. Adaramoye O. Antidiabetic effect of kolaviron, a biflavonoid complex isolated from Garcinia kola seeds, in Wistar rats. Afr Health Sci 2013, 12(4):498-506.
22. Iwu MM, Igboko OA, Okunji CO, Tempesta MS. Antidiabetic and aldose reductase activities of biflavanones of Garcinia kola. J Pharm Pharmacol 1990, 42(4):290-292. 10.1111/j.2042-7158.1990.tb05412.x, 1974302.
23. Waterman PG, Hussain RA. Systematic significance of xanthones, benzophenones and biflavonoids in Garcinia. Biochem Syst Ecol 1983, 11:21-28.
24. Wadkar K, Magdum C, Patil S, Naikwade N. Anti-diabetic potential and Indian medicinal plants. J Herb Med Toxicol 2008, 2(1):45-50.
25. Nwankwo JO, Tahnteng JG, Emerole G. Inhibzition of aflatoxin B1 genotoxicity in human liver-derived HepG2 cells by kolaviron biflavonoids and molecular mechanisms of action. Eur J Cancer Prev 2000, 9:351-361. 10.1097/00008469-200010000-00010, 11075889.
26. Ahrens B. Antibodies in metabolic diseases. New Biotechnol 2011, 28(5):530-537.
27. Li Y, Zhang Y, Liu D, Liu H, Hou W, Dong Y. Curcumin attenuates diabetic neuropathic pain by downregulating TNF-α in a rat model. Int J Med Sci 2013, 10(4):377. 10.7150/ijms.5224, 3590595, 23471081.
28. Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J, Li Y, Yan Y, Wang Z, Li X. Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. J Nutr Biochem 2012, 24:146-155.
29. Chang C, Chang C, Huang J, Hung L. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin J Physiol 2012, 55(3):192-201. 10.4077/CJP.2012.BAA012, 22784284.
30. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 2010, 56(25):2115-2125. 10.1016/j.jacc.2010.07.033, 3026637, 21144973.
31. Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011, 7(6):327-340. 10.1038/nrneph.2011.51, 21537349.
32. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005, 353:2643. 2637991, 16371630.
33. Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2008, 168(22):2440. 10.1001/archinte.168.22.2440, 2766035, 19064828.
34. Adaramoye O, Adeyemi E. Hypoglycaemic and hypolipidaemic effects of fractions from kolaviron, a biflavonoid complex from Garcinia Kola in streptozotocin-induced diabetes mellitus rats. J Pharm Pharmacol 2006, 58(1):121-128. 10.1211/jpp.58.1.0015, 16393472.
35. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese zucker rats and murine RAW 264.7 cells. J Nutr 2003, 133(5):1238-1243.
36. Pinent M, Blay M, Bladé MC, Salvadó MJ, Arola L. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology 2004, 145:4985-4990. 10.1210/en.2004-0764, 15271880.
37. Naik SR, Fliho JMB, Dhuley JN, Deshmukh A. Probable mechanism of hypoglycaemic activity of bassic acid, a natural product isolated from Bumelia sartorum. J Ethnopharmacol 1999, 33:37-44.
38. Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, Granner DK. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 2002, 277:34933-34940. 10.1074/jbc.M204672200, 12118006.
39. Sarkhail P, Rahmaipour S, Fadyevatan S, Mohammadirad A, Dehghan G, Amin G. Antidiabetic effect of Phlomis anisodonta: effects on hepatic cells lipid peroxidation and antioxidant enzymes in experimental diabetes. Pharmacol Res 2007, 56:261-266. 10.1016/j.phrs.2007.07.003, 17714953.
40. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004, 364(9447):1786-1788. 10.1016/S0140-6736(04)17402-3, 15541452.
41. Ravi K, Ramachandran B, Subramanian S. Protective effect of Eugenia jambolana seed kernel on tissue antioxidants in streptozotocin-induced diabetic rats. Biol Pharm Bull 2004, 27(8):1212-1217. 10.1248/bpb.27.1212, 15305024.
42. Rawi M, Mourad M, Sayed A. Biochemical and changes in experimental diabetes before and after treatment with Mangifera indica Psidium guava extracts. Int J Pharm Bio Sci 2011, 2(2):29-41.
43. Li X. Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int J Biol Macromol 2007, 40(5):461-465. 10.1016/j.ijbiomac.2006.11.002, 17166579.
44. Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K. Curcumin ameliorates macrophage infiltration by inhibiting NF-B activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metabol 2011, 8(1):35.
45. Banki E, Degrell P, Kiss P, Kovacs K, Kemeny A, Csanaky K, Duh A, Nagy D, Toth G, Tamas A. Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides 2013, 42:125-130.
46. Wu C, Chen J, Lu K, Chen C, Lin S, Chu P, Sytwu H, Lin Y. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010, 411(9):700-704.
47. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-179. 10.1146/annurev.nutr.012809.104755, 3144156, 20420526.
48. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009, 11(2):241-249. 10.1089/ars.2008.2140, 2933148, 18976114.
49. Viedt C, Orth SR. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?. Nephrol Dial Transplant 2002, 17(12):2043-2047. 10.1093/ndt/17.12.2043, 12454208.
50. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Ren Physiol 2008, 294(4):F697-F701.
51. Tous M, Ferré N, Rull A, Marsillach J, Coll B, Alonso-Villaverde C, Camps J, Joven J. Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun 2006, 340(4):1078-1084. 10.1016/j.bbrc.2005.12.109, 16403442.
52. Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, Ariyasu H, Akamizu T, Kita T, Yokode M. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008, 28(12):2195-2201. 10.1161/ATVBAHA.108.168633, 18818420.
53. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. New Engl J Med 2000, 343:1467-1476. 10.1056/NEJM200011163432007, 11078773.
54. Solt LA, Madge LA, Orange JS, May MJ. Interleukin-1-induced NF-κB activation is NEMO-dependent but does not require IKKβ. J Biol Chem 2007, 282(12):8724-8733. 10.1074/jbc.M609613200, 2824644, 17244613.
55. Ingaramo PI, Ronco MT, Francés DE, Monti JA, Pisani GB, Ceballos MP, Galleano M, Carrillo MC, Carnovale CE. Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes mellitus. Mol Immunol 2011, 48(12):1397-1407.
56. Gui D, Huang J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, Wang N. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB- mediated inflammatory genes expression. Cytokine 2013, 61:970-977. 10.1016/j.cyto.2013.01.008, 23434274.
57. Cnop M, Welsh N, Jonas J, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β- Cell death in type 1 and type 2 diabetes, many differences, few Similarities. Diabetes 2005, 54(suppl 2):S97-S107.
58. Ehses J, Lacraz G, Giroix M, Schmidlin F, Coulaud J, Kassis N, Irminger J, Kergoat M, Portha B, Homo-Delarche F. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci 2009, 106(33):13998-14003. 10.1073/pnas.0810087106, 2729009, 19666548.
59. Ding W, Yin X. Dissection of the multiple mechanisms of TNF-α-induced apoptosis in liver injury. J Cell Mol Med 2004, 8(4):445-454. 10.1111/j.1582-4934.2004.tb00469.x, 15601573.
60. Olaleye S, Onasanwo S, Ige A, Wu K, Cho C. Anti-inflammatory activities ofa kolaviron- inhibition of nitric oxide, prostaglandin E2 and tumor necrosis factor-alpha production in activated macrophage-like cell line. Afr J Med Med Sci 2010, 39:41-46.
61. Farombi EO, Shrotriya S, Surh Y. Kolaviron inhibits dimethyl nitrosamine-induced liver injury by suppressing COX-2 and iNOS expression via NF-κB and AP-1. Life Sci 2009, 84(5-6):149-155.